A naukri.com initiative
Bioengineer
5d
154
Image Credit: Bioengineer
Asthma Drug Fails to Treat Alcoholism Except in Select Group, Study Finds
- A recent study explored the use of the asthma drug ibudilast for treating alcohol use disorder (AUD) but found limited success overall.
- The study involved 102 adults with moderate to severe AUD who received ibudilast or a placebo for 12 weeks, with monitoring for four additional weeks.
- Although ibudilast did not significantly decrease alcohol consumption compared to placebo overall, interesting sex-specific responses were observed.
- Female participants showed a significant reduction in drinks per day with ibudilast, potentially attributed to higher baseline inflammation levels in women.
- Conversely, individuals with high depressive symptoms did not benefit from ibudilast, indicating a complex interaction between mood disorders and treatment efficacy.
- While ibudilast did not reduce inflammation markers significantly, the study highlighted the need for longer trials to assess sustained effects and personalized treatment approaches.
- The study emphasized the role of neuroinflammation in AUD and the potential for immune-targeting therapies in addiction treatment.
- Despite the challenges in developing AUD medications, the study offers insights into gender-specific responses and the importance of multidimensional phenotyping in clinical trials.
- Future research aims to identify subpopulations that may benefit more from ibudilast and advance precision medicine in AUD therapeutics.
- The study's findings underscore the complexity of addiction biology and the ongoing quest to develop effective treatments for alcoholism.
- While ibudilast's outcomes were nuanced, the study provides valuable insights that guide future inquiries and offer hope for improved medications in combating AUD.
Read Full Article
9 Likes
For uninterrupted reading, download the app